Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.720
+0.110 (4.21%)
At close: Jan 22, 2026, 4:00 PM EST
2.710
-0.010 (-0.37%)
After-hours: Jan 22, 2026, 6:12 PM EST
Aytu BioPharma Employees
As of June 30, 2025, Aytu BioPharma had 83 total employees, including 82 full-time and 1 part-time employees. The number of employees decreased by 16 or -16.16% compared to the previous year.
Employees
83
Change (1Y)
-16
Growth (1Y)
-16.16%
Revenue / Employee
$767,422
Profits / Employee
-$157,482
Market Cap
27.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 83 | -16 | -16.16% | 82 | 1 |
| Jun 30, 2024 | 99 | -51 | -34.00% | 99 | 0 |
| Jun 30, 2023 | 150 | -14 | -8.54% | 150 | 0 |
| Jun 30, 2022 | 164 | -11 | -6.29% | 164 | 0 |
| Jun 30, 2021 | 175 | 100 | 133.33% | 175 | 0 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AYTU News
- 2 days ago - Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript - Seeking Alpha
- 2 days ago - Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - Accesswire
- 9 days ago - Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - Accesswire
- 10 days ago - Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - Accesswire
- 5 weeks ago - Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - Accesswire
- 5 weeks ago - Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Accesswire
- 2 months ago - Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Accesswire
- 2 months ago - Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript - Seeking Alpha